MONTREAL, Aug. 7, 2017 /CNW Telbec/ - The Institute for Research in Immunology and Cancer (IRIC) of the Universit de Montral (UdeM) is pleased to announce that the UdeM Executive Committee has reappointed Mr.Robert Tessier as Chairman of the Board and has appointed Ms.Lucie Rmillard as a Board member.

The IRIC welcomes with great enthusiasm Mr.Tessier's reappointment and looks forward to his three-year mandate. Mr.Tessier is also Chairman of the Board of Directors of the Caisse de dpt et placement du Qubec.

Drawing on 12 years of active involvement with the organization, Mr.Tessier, as Chairman of the Board, will be surrounded by a team of dedicated collaborators sharing a wealth of expertise and various academic, business and philanthropic networks which they may call upon.

The IRIC will now be able to rely on the support of Lucie Rmillard, a corporate director with an extensive knowledge of the philanthropic sector acquired over the years, on the multifaceted work experience of Frdric Bouchard, Dean of the Faculty of Arts and Sciences (FAS) of the UdeM, as well as the dedication of current Board members: Dr.Marie-Jose Hbert, Vice-Rector of Research, Discovery, Creation and Innovation at the UdeM, Dr. Hlne Boisjoly, Dean of the UdeM's Faculty of Medicine, Jacques Bernier, Managing Partner at Teralys Capital, Marie-Jose Coutu, President of the Marcelle and Jean Coutu Foundation, Jean Royer, Vice-President of Distinction Capital, Michel Bouvier, Chief Executive Officer and Principal Investigator at the IRIC, and Marc Therrien, Scientific Director and Principal Investigator at the IRIC.

"The IRIC is truly fortunate to be able to count on a Board of such high calibre which, through its commitment and dedication to research, continues to support the Institute's objectives and development." Michel Bouvier, Chief Executive Officer and Principal Investigator at the IRIC

The IRIC would like to take this opportunity to extend its heartfelt thanks to the Board's outgoing members for their involvement and unwavering support throughout their mandate. Many thanks to Tania Saba, former interim Dean at the UdeM's FAS as well as Tenured professor of the UdeM, to Grard Boismenu, Vice-Rector of Academic Development and Institutional Transformation of the UdeM, to Johane Boucher-Champagne, former Chair of IRICoR's Board of Directors, and Jacques Parisien, director and advisor for several Canadian companies.

About the Institute for Research in Immunology and Cancer (IRIC)An ultra-modern research hub and training centre located in the heart of the Universit de Montral, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. The IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information: http://www.iric.ca/en/

SOURCE Institut de recherche en immunologie et en cancrologie de l'Universit de Montral

For further information: or interviews: Catherine Cardinal, Chief, Communication and media relations, 514 343-6111, ext. 41299, catherine.cardinal@umontreal.ca; Cristina Annunzi, Advisor, Communication and media relations, 514 343-7283, cristina.annunzi@umontreal.ca

Read more here:
Appointment and reappointment to the Institute for Research in Immunology and Cancer of the Universit de Montral ... - Canada NewsWire (press release)

Dr. Gregory Sonnenberg, an assistant professor of microbiology and immunology at Weill Cornell Medicine, has received the newly established Young Investigator Award from the Society for Mucosal Immunology.

The award honors investigators within 15 years of their postdoctoral training who have made significant contributions to the field of mucosal immunology, which is the study of immune responses that occur in the intestines, lungs and urogenital tract.

Dr. Sonnenberg accepted his award at the 18th International Congress of Mucosal of Immunology on July 19 in Washington, D.C. The award carries a cash prize and additional funds to support Dr. Sonnenbergs laboratory.

Dr. Greg Sonnenberg accepts his award from society President Dr. Allan Mowat. Photo credit: Society for Mucosal Immunology

It is an enormous honor to receive this award from the Society for Mucosal Immunology in acknowledgement of my laboratorys research contributions, said Dr. Sonnenberg, who is also a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine. It is truly a testament to the outstanding advisors, past and present lab members, and collaborators I had the pleasure of working with throughout my career.

Dr. Sonnenbergs research centers on better understanding the processes that maintain a healthy state in the human gastrointestinal tract. Specifically, he and his team are focused on the relationship between beneficial or commensal bacteria which live in the intestine and are important for digestion and the maturation of the immune system and their mammalian hosts.

While the relationship between commensal bacteria and their hosts is normally beneficial, the immune system attacks these good bacteria and causes chronic inflammation associated with numerous human diseases, such as inflammatory bowel disease, HIV/AIDS, viral hepatitis, cardiovascular disease, obesity, asthma, diabetes and cancer. His team is investigating why the immune system changes course and disrupts the normally beneficial relationship. Their aim is to determine how to restore this relationship to its positive state.

Recent studies at Dr. Sonnenbergs lab have focused on an emerging family of immune cells, which play a role in regulating interactions between the commensal bacteria and the immune system, called intestinal-resident innate lymphoid cells (ILCs). Some of the research from Dr. Sonnenbergs laboratory has highlighted the ILCs ability to tell the immune system not to attack commensal bacteria.

The ILCs could hold an important key to restoring beneficial interactions between microbes in the gut and the immune system to limit chronic inflammation associated with many different diseases, Dr. Sonnenberg said.

Ongoing research will look at ILC responses and interactions with commensal bacteria in healthy and diseased tissue samples. The lab plans to translate their findings from mouse models into clinically relevant information that will help develop therapies to treat chronic diseases.

Read the original post:
Dr. Gregory Sonnenberg Wins Inaugural Award from the Society for Mucosal Immunology - Cornell Chronicle

HumanZyme Inc. announces the launch of recombinant human Interferon beta expressed from HEK293 cells for research purposes. HumanZyme's HumanKine IFN beta has native processing, glycosylation and folding, preserving its biologic function and activity. HumanZyme's HumanKine proteins are animal product-free, xeno-free and carrier-free.

Chicago, IL (PRWEB) August 08, 2017

HumanZyme Inc., a leading supplier of novel recombinant human proteins and growth factors expressed in human cells, today announced the launch of HumanKine Interferon beta (IFN beta) expressed from HEK293 cells. IFN beta isa member of the type I family of interferonsthat activate Th1-type innate immune responses against viral and bacterial infection, and have antiproliferative and immunomodulatory functions.IFN beta is currently FDA-approved in injectable form as a treatment for multiple sclerosis, an autoimmune disease, and has been investigated for use in cancer therapeutics for its anti-tumor activity.

According to Scott Coleridge, CEO at HumanZyme, "We are proud to be the only commercial supplier of high-quality, tag-free recombinant human Interferon beta expressed in human cells for research purposes. Our proprietary HEK293 expression system allows us to express difficult proteins in a human cell line to provide the most authentic recombinant products possible. The new IFN beta further expands our animal component-free HumanKine product line, and the product is priced competitively and also available in bulk."

Glycosylation of the IFN beta protein by a single asparagine-linked sugar chain is essential to its activity and stability, both in vitro and in vivo. IFN beta purified from human cells has been shown to have the highest biologic activity and stability compared to recombinant human IFN beta produced in non-human expression systems. HumanZyme's recombinant human IFN beta expressed in human cells assures native processing, glycosylation and folding of the purified protein compared to bacterial, mammalian cell lines, or insect cell expression systems, preserving its biologic function and activity. HumanZyme's HumanKine proteins are also animal-derived product free, xeno-free and carrier-free.

For more information, see our Interferon beta product page.

About HumanZyme, Inc.:HumanZyme, Inc. is the global leader in providing highly authentic recombinant human proteins from human cells. Our process is cost-effective and scalable making our proteins suitable for the research, diagnostic, drug discovery and biopharmaceutical markets. HumanZyme leverages its proprietary engineered human cells, expression vector, and cell culture media to ensure high-yield production of recombinant proteins with native human post-translational modifications. We are a leading provider of cytokines and growth factors and a preferred outsourcing supplier of human protein production. Our products and services support a broad range of customers worldwide, from academic and government research institutions to biotechnology and pharmaceutical companies.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/08/prweb14577825.htm

View original post here:
HumanZyme Announces Human Cell-Expressed Interferon beta for Immunology and Immunotherapy Research ... - Benzinga

MONTREAL, Aug. 7, 2017 /CNW Telbec/ - The Institute for Research in Immunology and Cancer (IRIC) of the Universit de Montral (UdeM) is pleased to announce that the UdeM Executive Committee has reappointed Mr.Robert Tessier as Chairman of the Board and has appointed Ms.Lucie Rmillard as a Board member.

The IRIC welcomes with great enthusiasm Mr.Tessier's reappointment and looks forward to his three-year mandate. Mr.Tessier is also Chairman of the Board of Directors of the Caisse de dpt et placement du Qubec.

Drawing on 12 years of active involvement with the organization, Mr.Tessier, as Chairman of the Board, will be surrounded by a team of dedicated collaborators sharing a wealth of expertise and various academic, business and philanthropic networks which they may call upon.

The IRIC will now be able to rely on the support of Lucie Rmillard, a corporate director with an extensive knowledge of the philanthropic sector acquired over the years, on the multifaceted work experience of Frdric Bouchard, Dean of the Faculty of Arts and Sciences (FAS) of the UdeM, as well as the dedication of current Board members: Dr.Marie-Jose Hbert, Vice-Rector of Research, Discovery, Creation and Innovation at the UdeM, Dr. Hlne Boisjoly, Dean of the UdeM's Faculty of Medicine, Jacques Bernier, Managing Partner at Teralys Capital, Marie-Jose Coutu, President of the Marcelle and Jean Coutu Foundation, Jean Royer, Vice-President of Distinction Capital, Michel Bouvier, Chief Executive Officer and Principal Investigator at the IRIC, and Marc Therrien, Scientific Director and Principal Investigator at the IRIC.

"The IRIC is truly fortunate to be able to count on a Board of such high calibre which, through its commitment and dedication to research, continues to support the Institute's objectives and development." Michel Bouvier, Chief Executive Officer and Principal Investigator at the IRIC

The IRIC would like to take this opportunity to extend its heartfelt thanks to the Board's outgoing members for their involvement and unwavering support throughout their mandate. Many thanks to Tania Saba, former interim Dean at the UdeM's FAS as well as Tenured professor of the UdeM, to Grard Boismenu, Vice-Rector of Academic Development and Institutional Transformation of the UdeM, to Johane Boucher-Champagne, former Chair of IRICoR's Board of Directors, and Jacques Parisien, director and advisor for several Canadian companies.

About the Institute for Research in Immunology and Cancer (IRIC)An ultra-modern research hub and training centre located in the heart of the Universit de Montral, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. The IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information: http://www.iric.ca/en/

SOURCE Institut de recherche en immunologie et en cancrologie de l'Universit de Montral

Continue reading here:
Appointment and reappointment to the Institute for Research in ... - Markets Insider

DrugPipeline.net has announced the addition of Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth research report to their website http://www.DrugPipeline.net

This press release was orginally distributed by SBWire

Bangalore, India -- (SBWIRE) -- 08/07/2017 -- Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth

Summary

Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and mobility loss, and have a negative impact on quality of life.

A number of therapies have been approved for immunological disorders, including the largely genericized disease-modifying anti-rheumatic drug (DMARD) class of small molecule drugs. However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. There is currently no cure for immunological disorders due to the highly complex nature of the immune system and the fact that many components of the pathophysiological states of these diseases have roles in the healthy immune system.

Autoimmune disorders are currently incurable, and treatment is aimed at managing the disease, in order to reduce the severity of its symptoms and lower the risk of associated co-morbidities. Cytokines and their receptors, such as Tumor Necrosis Factor-? and Interleukin-6 are the most effective and most common therapies used in immunology. This class of compounds has been the most commercially successful in the past decade, particularly in the RA market, with many clinical trials underway across various immunological indications. The market for immunological disorders is largely accounted for by premium products, with only a relatively small revenue share accounted for by generics and biosimilars.

Inflectra, a biosimilar of Remicade was recently approved by the FDA in 2016. However, the gradual uptake of biosimilars such as Inflectra is not expected to act as a strong growth driver for the biosimilar segment within the forecast period. This therefore means existing products such as Remicade are expected to maintain high revenues during the forecast period

Although there is a high degree of failure and uncertainty in R&D of immunological drugs, there are 2,054 drugs in active development in the immunology pipeline. In the long-term, this is expected to drive growth in this market in spite of the anticipated approval of biosimilars for key blockbuster drugs and resultant erosion of revenues. Cytokines and their receptors account for the largest single segment of each of the pipelines which make up the largest individual class.

The report focuses on four key indications within immunology: Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Psoriasis and Inflammatory bowel disease (The two major types of Inflammatory bowel disease covered in this report are Ulcerative colitis and Crohn's disease). With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in SLE, increasing the need for extensive R&D within this area.

Scope

- Global revenues for the immunology market are forecast to grow at a compound annual growth rate of 3.63%, from $57.7 billion in 2015 to $74.1 billion in 2022.

- Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?

- The immunological disorders pipeline is large and diverse, and contains 2,054 products. How does the composition of the pipeline compare with that of the existing market?

- What molecular targets and molecule types are most commonly being trialed in pipeline products in the key indications?

- Which products will contribute to market growth most significantly, and which will achieve blockbuster status?

- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the immunology market set to change?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis

- Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players

- Analyze the immunological disorders pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications

- Understand the growth in patient epidemiology and market revenues for the immunology market, globally and across the key players and product types

- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various immunological disorders.

- Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals

Spanning over 140 pages "Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth" report covers Introduction, Key Marketed Products, Pipeline Landscape Assessment, Multi-scenario Market Forecast to 2022, Company Analysis and Positioning, Strategic Consolidations, Appendix.

For more information Visit at: http://www.drugpipeline.net/gbi-research/global-immunology-drugs-market-2022-increasing-prevalence-repositioning-opportunities

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Pain Drug Development Pipeline Review, 2017 - Visit at - http://www.drugpipeline.net/gbi-research/pain-drug-development-pipeline-review-2017

Skeletal Disease Drug Development Pipeline Review, 2017 - Visit at - http://www.drugpipeline.net/gbi-research/skeletal-disease-drug-development-pipeline-review-2017

About DrugPipeline.netDrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

For more information on this press release visit: http://www.sbwire.com/press-releases/global-immunology-drugs-market-to-2022-new-report-launched-843163.htm

See the article here:
Global Immunology Drugs Market to 2022; New Report Launched - Digital Journal

Boys Town National Research Hospital

Boys Town Allergy, Asthma Immunology & Pediatric Pulmonology Welcomes New Physician

Brian T. Kelly, M.D., M.A. joined Boys Town Allergy, Asthma & Immunology on August 1, 2017 from St. Paul Allergy and Asthma in Minnesota. He received his medical degree from the University of Missouri-Kansas City School of Medicine and completed his pediatric residency at Children's Hospital of Wisconsin. In addition, Dr. Kelly completed a fellowship in allergy/clinical immunology at the Medical College of Wisconsin. He is board certified in pediatrics and allergy/immunology. He is accepting new patients at Boys Town Pediatrics Lakeside Clinic located at 16929 Frances Street, Suite 101.

Read the original:
Boys Town Allergy, Asthma Immunology & Pediatric Pulmonology - Omaha World-Herald

A nationwide manhunt is underway for a Northwestern University professor and an Oxford University employee who are wanted as suspects after a man was found fatally stabbed inside a luxury Chicago apartment, police said.

On Monday, first-degree murder warrants without bail were issued for Wyndham Lathem, 42, and Andrew Warren, 56, for their alleged involvement in the death of Trenton H. James Cornell-Duranleau, Cook County court records show.

The documents say Cornell-Duranleau, 26, died after being stabbed multiple times. A community alert released by the Chicago Police Department says the body was discovered on July 27.

via Facebook

Officers received a call and arrived at the Grand Plaza Apartments and found the victim with several lacerations on his body. Cornell-Duranleau was pronounced dead on the scene and detectives are investigating the stabbing as a homicide while police actively search for the two suspects, officials said.

Lathem has been an associate professor of microbiology and immunology at Northwestern University since 2007. Alan K. Cubbage, the vice president for university relations, said in an emailed statement that Lathem is now on administrative leave and has been banned from entering Northwestern University campuses.

Wyndham Lathem is an associate professor of microbiology and immunology at Northwestern University. Chicago Police via AP

This is now a criminal matter under investigation by the appropriate authorities, and Northwestern University is cooperating in that investigation, Cubbage said.

Warren is a senior treasury assistant at Oxford University. A spokesperson for the university and Somerville College said in an emailed statement that, We have been in contact with the police in the UK and are ready to help the US investigating authorities in any way they need. The statement added that Warrens colleagues were shocked and want him to turn himself in.

Oxford University employee Andrew Warren Chicago Police via EPA

Chief Communications Officer of the Chicago Police Department Anthony Guglielmi said he strongly encourages the suspects to surrender to authorities. Police have an idea of their whereabouts but our efforts to locate that are intensifying, Guglielmi said.

Guglielmi said local, regional and national authorities are helping find the suspects. Guglielmi said police received a call from the Grand Plaza building manager who had just received a cryptic tip that said something had occurred in apartment 1008. Police described the scene as very gruesome. Guglielmi said it is unclear if the incident also occurred on July 27. Lathem and Warren were confirmed to be at the building by security cameras, he said.

Police said Lathem lived at the apartment that has since been identified as the crime scene.

We believe Professor Latham and the victim had a relationship, Guglielmi said. He added that both suspects' passports and Warren's travel visa have been flagged. Police also confirmed that the two suspects donated $1,000 to a Wisconsin library in the victim's name.

The management team at Grand Plaza said in a statement to residents: Police are currently working on the timeline and background of the victim and are exploring a variety of motives, including a possible domestic incident.

Continued here:
Northwestern Professor and Oxford University Employee Wanted for Homicide - NBCNews.com

A Northwestern University associate professor and a University of Oxford employee are wanted in connection with the stabbing death of a man in a Near North Side apartment, according to public records. A Cook County judge issued arrest warrants Monday charging Wyndham Lathem, 42, and Andrew Warren, 56, with first-degree murder in the death of 26-year-old Trenton Cornell-Duranleau last week, records show.

An alert broadcast over police radio says the two should be considered armed and dangerous. Late Wednesday afternoon, Chicago police spokesman Anthony Guglielmi reported no arrests.

"Our search will only intensify,'' tweeted Guglielmi. "Prof Latham (Lathem) & Mr Warren, do the right thing & turn yourself in to any police dept.''

Lathem is an associate professor at Northwestern's Department of Microbiology-Immunology at the Feinberg School of Medicine. In his LinkedIn profile, Lathem said his research is focused on pathogens and the diseases they cause.

Lathem has been placed on administrative leave and is banned from all Northwestern campuses, according to school spokesman Alan K. Cubbage. He was a faculty researcher at the school's Chicago campus.

The university is cooperating with the police investigation, Cubbage said.

Warren is a senior treasury assistant at Somerville College, part of the Oxford University network, according to a university web page. Chicago police officers responded to a 10th-floor apartment in the 500 block of North State Street about 8:30 p.m. Thursday after a maintenance worker reported getting an anonymous call that a crime was committed there. Officers found Cornell-Duranleau dead on the scene. Lathem lists his home at the same address on State Street, public records show. The building is on the same block as the Grand Avenue Red Line station.Cornell-Duranleau died of multiple sharp force injuries, according to the Cook County medical examiners office. He had lived in the 2200 block of South Wood Street in the Heart of Chicago neighborhood on the Near Southwest Side, the office said.

He grew up in Michigan, according to public records. Cornell-Duranleau earned a state license as a cosmetologist in 2011, according to the Michigan Department of Licensing and Regulatory Affairs.

Chicago Police Department

His mother, Mischelle Duranleau, posted a message on Facebook over the weekend asking for prayers "as we navigate this very dark part of our Journey."

According to an obituary posted by the mother, Cornell-Duranleau was born in Lennon, Mich., a small town about 50 miles northeast of Lansing.

"Throughout his life he loved music and animals," the obituary said. "His enthusiasm for life was infectious. Trenton was a caregiver and loved to help others. His youthful free-spirit fueled his love of cars, video games and cartoons."

Northwestern was made aware of the investigation into Cornell-Duranleau's death on Monday afternoon, Cubbage said.

Lathem has been with Northwestern since 2007, according to Cubbage, who said he worked primarily in a research lab. "At some point in the past few years he taught medical students or graduate students, never undergrad, Cubbage said.

Lathem was not currently teaching and was not scheduled to be in a classroom in the fall, Cubbage said.

Oxford University, where the other suspect worked, released a statement Tuesday saying it was "not aware of this case, which is clearly extremely concerning. We will liaise with the relevant investigating authorities and provide any assistance that is required.

More:
Arrest warrant issued for Northwestern professor in Near North Side stabbing death - Chicago Tribune

Shire has kickstarted a strategic review of its ADHD drugs business which could see the FTSE 100 giant broken up into two stock exchange-listed parts, after posting consensus-beating half-year sales and profits growth.

Flemming rnskov, chief executive at Shire, said the groups US-focused neurosciences division set to make up around a fifth of its projected $14.3bn-$14.6bn (10.9bn-11.1bn) sales this year was an incredibly strong business that could stand alone.

The strategic review will complete this year, with the firm saying it could result in neurosciences getting an independent public listing. Mr rnskov declined to say whether London or New York was the more likely candidate.

Given the USs large appetite for ADHD drugs, New York could hold appeal.Julie Simmonds, analyst at Panmure, commented: Its something they could look at, it would make as much sense as it would here.

Any separation would allow Shire to focus on its rare diseases business, which accounts for the bulk of revenues and a wide gamut of treatments across immunology, haematology, internal medicine, eye ailments, oncology and anti-virals.

Read the original here:
Shire eyes spin-out of its ADHD drugs arm - Telegraph.co.uk

MONTREAL, July 31, 2017 /CNW Telbec/ - IRICoR (Institute for Research in Immunology and Cancer - Commercialization of Research) proudly announces the appointment of Dr. Martin Godbout, president of Hodran Consultants Inc., as the new Chairman of its Board of Directors and of Ms. Catherine Bouchard, Head of Research, Life Sciences at the Caisse de dpt et placement du Qubec, as a new Board member.

Dr. Godbout brings to IRICoR's Board a deep expertise in the health sciences sector. With his thorough knowledge of the field and his close to 30-year experience, he will greatly contribute to IRICoR's ongoing initiatives to attract and accelerate the development of promising innovative projects in oncology. Dr. Godbout started his professional career as President and CEO of Socit Innovatech Qubec, a technology-focused venture capital (VC) fund. He then served as Executive Vice-president of BioCapital, a biopharmaceutical VC firm, after which he founded Genome Canada, which he successfully led for more than 10 years as CEO. He was also a Board member of numerous biopharmaceutical companies, not-for-profit organizations involved in funding research and innovation and philanthropic organizations. He is currently Chair of the Board at Amorchem-I, BioContact, BioQubec and Genome Quebec, and a Board Member of various organizations, including the Fonds de recherche du Qubec Sant. Dr. Godbout holds a B.Sc. in Biochemistry and a Ph.D. in Physiology and Molecular Endocrinology from Universit Laval. He completed his post-doctoral training in Molecular Neurobiology at San Diego'sScripps Research Institute. Finally, Dr. Godbout is an Officer at the Order of Canada.

"We enthusiastically welcome Dr. Godbout to IRICoR's team. His diverse professional expertise both in the healthcare and business sectors, as well as his broad professional network will be critical to the success of IRICoR's ongoing strategic initiatives."Nadine Beauger, Chief Executive Officer - IRICoR

Dr. Godbout succeeds Johane Boucher-Champagne who was Chair of IRICoR's Board since 2011, after having been a member since 2009. IRICoR takes this opportunity to formally thank Mrs. Boucher-Champagne for having put her deep experience in the life science sector to the service of IRICoR. She has truly been a key resource for the organization through all those years.

"Through her deep knowledge of the pharmaceutical sector and her keen governance skills, Mrs. Boucher-Champagne skillfully managed to further IRICoR's initiatives, leading the organization to become a leader in commercialization of research. We are very grateful for Mrs. Boucher-Champagne's 8 years of continuous commitment."Michel Bouvier, Chief Executive Officer and Principal Investigator, IRIC (Institute for Research in Immunology and Cancer)

Catherine Bouchard has more than 10 years of experience in healthcare equity research. She is currently Head of Research, Life Sciences at the Caisse de dpt et placement du Qubec, where she has served as Senior Healthcare Analyst since 2012. Prior to joining CDPQ, Ms. Bouchard spent 5 years at Valeurs Mobilires Banque Laurentienne, where she was the Lead Analyst covering healthcare stocks. Her expertise in industry analysis and her deep knowledge of the healthcare sector will be key additions for IRICoR. She holds a B.Sc. in Microbiology and Immunology and an M.Sc. in Biomedical Sciences from Universit de Montral, as well as an MBA from HEC Montreal.

Dr. Godbout and Ms. Bouchard are joining a Board that stands out for its Members' deep commitment, diverse expertise in both health sciences and business matters, as well as its extended network.

About the Institute for Research in Immunology and Cancer Commercialization of Research (IRICoR)

As Universit de Montral's drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC), with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive potential to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR: http://www.iricor.ca

About the Institute for Research in Immunology and Cancer (IRIC)

An ultra-modern research hub and training centre located in the heart of the Universit de Montreal, the Institute for Research in Immunology and Cancer (IRIC) was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For further information visit http://www.iric.ca

About the University of Montreal

Deeply rooted in Montreal and dedicated to its international mission, the University of Montreal is one of the top 100 universities in the world. It was founded in 1878, and together with its two affiliated schools, HEC Montral and Polytechnique Montral, constitutes the largest centre of higher education and research in Quebec and one of the major centres in North America. The University of Montreal brings together more than 2,700 professors and researchers and welcomes more than 68,000 students. http://www.umontreal.ca

SOURCE Institut de recherche en immunologie et en cancrologie de l'Universit de Montral

Continue reading here:
IRICoR announces the appointment of Dr. Martin Godbout as Chairman of its Board of Directors and of Ms. Catherine ... - Markets Insider